Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.

Lana Zhovtis RyersonJohn FoleyIh ChangIlya KisterGary R CutterRyan R MetzgerJudith D GoldbergXiaochun LiEvan RiddleKaren SmirnakisRachna KasliwalZheng RenChristophe HotermansPei-Ran HoNolan Campbell

Published in: Neurology (2019)

This study provides Class III evidence that for patients with MS, natalizumab EID is associated with a lower PML risk than SID.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms